Comparison of Clinical Outcomes Between Calfactant and Poractant-Alfa in Preterm Infants with Respiratory Distress Syndrome
Compared with calfactant, poractant alfa offers practical advantages-such as a higher initial dose, lower cost, and reduced need for a second repeat dose-while yielding comparable short- and mid-term morbidity and mortality outcomes.
Authors
- Leyla Şero (ORCID: https://orcid.org/0000-0001-5224-8583)
- Nilüfer Okur (ORCID: https://orcid.org/0000-0002-0027-0532)
- Duygu Tunçel (ORCID: https://orcid.org/0000-0002-2130-6821)
Institutions
- Diyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi (TR)
Publication Details
- Journal
- Children
- Published
- 2025-10-08
- DOI
- https://doi.org/10.3390/children12101350
- Primary Topic
- Neonatal Respiratory Health Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00